Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
Abstract
The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active angiotensin-I-converting-enzyme inhibitor, captopril. The plasma concentration of aldosterone decreased initially from 74 to 21 pg/ml (P less than 0.05) after 1 month of administration of captopril. Thereafter the plasma concentration of aldosterone began to rise and after 1 year reached a level of 165 pg/ml. During long-term captopril therapy the plasma renin activity remained increased and the plasma angiotensin II concentration suppressed. The mechanism responsible for the late rise of the plasma concentration of aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. A sizeable and lasting hypotensive effect was observed in all patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Experimental evidence suggests that RAS blockade leads to incomplete suppression of serum aldosterone levels (aldosterone escape phenomenon), offering an opportunity to consider additional treatment options to lower residual albuminuria and ameliorate kidney fibrosis.
“Experimental evidence suggests that RAS blockade leads to incomplete suppression of serum aldosterone levels (aldosterone escape phenomenon), offering an opportunity to consider additional treatment options to lower residual albuminuria and ameliorate kidney fi brosis.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [154]
Cites
Still being checked.
Cited by
Sorted by citations
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · see citing works
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,583 · see citing works
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373 · see citing works
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 500 · see citing works
(1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00465-1 · Cited by 491 · see citing works
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · see citing works
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 440 · see citing works
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0575 · Cited by 418 · see citing works
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 386 · see citing works
Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01116-0 · Cited by 367 · see citing works
Pitt, B., Williams, G. H., Remme, W. J., Martínez, F., Lopez-Sendon, J. L., Zannad, F. M., Neaton, J. D., Roniker, B., Hurley, S., Burns, D. M., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 359 · see citing works
Latini, R. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.10.030 · Cited by 344 · see citing works
Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Zuckerman, A. L., & Stier, C. T. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.232 · Cited by 310 · see citing works
Parving, H. ‐., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M. M., Weissbach, N., Xiang, Z., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn721 · Cited by 303 · see citing works
Cleland, J. G. F., Dargie, H. J., Ball, S. G., Gillen, G., Hodsman, G. P., Morton, J. J., East, B. W., Robertson, I., Ford, I., & Robertson, J. I. S. (1985) · Heart · doi:10.1136/hrt.54.3.305 · Cited by 277 · see citing works
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04750908 · Cited by 266 · see citing works
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261 · see citing works
Aldosterone antagonists for preventing the progression of chronic kidney disease
Bolignano, D., Palmer, S. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub3 · Cited by 249 · see citing works
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
Struthers, A. D. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80009-1 · Cited by 226 · see citing works
Suzuki, G., Morita, H., Mishima, T., Sharov, V. G., Todor, A. V., Tanhehco, E. J., Rudolph, A. E., McMahon, E. G., Goldstein, S., & Sabbah, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000039104.56479.42 · Cited by 214 · see citing works
Pitt, B. (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877755 · Cited by 203 · see citing works
The role of spironolactone in the treatment of patients with refractory hypertension
Ouzan, J. M., Perault, C., Lincoff, A. M., Carre, E., & Mertès, P. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02342-1 · Cited by 203 · see citing works
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180 · see citing works
Aldosterone antagonists for preventing the progression of chronic kidney disease
Navaneethan, S. D., Nigwekar, S. U., & Strippoli, G. F. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004 · Cited by 166 · see citing works
Yee, K.-M., Pringle, S. D., & Struthers, A. D. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01243-8 · Cited by 159 · see citing works
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Segall, L., Nistor, I., & Covic, A. C. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 160 · see citing works
Brown, N. J. (2003) · Circulation · doi:10.1161/01.cir.0000071081.35693.9a · Cited by 158 · see citing works
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
Epstein, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80115-3 · Cited by 157 · see citing works
Bauersachs, J. K., Heck, M., Fraccarollo, D., Hildemann, S. K., Ertl, G., Wehling, M., & Christ, M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01729-6 · Cited by 151 · see citing works
Sato, A., & Saruta, T. (2001) · Journal of International Medical Research · doi:10.1177/147323000102900103 · Cited by 148 · see citing works
Furosemide and the progression of left ventricular dysfunction in experimental heart failure
McCurley, J. M., Hanlon, S. U., Wei, S.-K., Wedam, E. F., Michalski, M., & Haigney, M. C. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.04.059 · Cited by 143 · see citing works
Duprez, D. A., Bauwens, F. R., De Buyzere, M. L., De Backer, T. L., Kaufman, J. M., Van Hoecke, J., Vermeulen, A., & Clement, D. L. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90240-d · Cited by 139 · see citing works
Tandon, P., Abraldeṣ, J. G., Berzigotti, A., García‐Pagán, J. C., & Bosch, J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.013 · Cited by 134 · see citing works
Katayama, S., Yamada, D., Nakayama, M., Yamada, T., Myoishi, M., Kato, M. C., Nowack, C., Kolkhof, P., & Yamasaki, Y. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.021 · Cited by 133 · see citing works
Ramires, F. J. A., Mansur, A. D. P., Coelho, O. R., Maranhão, M., Gruppi, C. J., Mady, C., & Ramires, J. A. F. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00729-3 · Cited by 132 · see citing works
Naruse, M., Tanabe, A., Sato, A., Takagi, S., Tsuchiya, K., Imaki, T., & Takano, K. (2002) · Hypertension · doi:10.1161/01.hyp.0000022606.52221.2f · Cited by 129 · see citing works
Aldosterone as a Mediator in Cardiovascular Injury
Stier, C. T., Chander, P. N., & Rocha, R. (2002) · Cardiology in Review · doi:10.1097/00045415-200203000-00008 · Cited by 128 · see citing works
Aldosterone and Myocardial Fibrosis in Heart Failure
Brilla, C. G. (2000) · Herz · doi:10.1007/s000590050024 · Cited by 128 · see citing works
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy
Sato, A. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00913-0 · Cited by 125 · see citing works
Beta-Blocker Therapy for Cardiac Dysfunction in Patients With Muscular Dystrophy
Kajimoto, H., Ishigaki, K., Okumura, K., Tomimatsu, H., Nakazawa, M., Saito, K., Ōsawa, M., & Nakanishi, T. (2006) · Circulation Journal · doi:10.1253/circj.70.991 · Cited by 117 · see citing works
Julian, B. A., & Novák, J. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200403000-00005 · Cited by 112 · see citing works
Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease
Epstein, M. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.038 · Cited by 111 · see citing works
Aldosterone and antialdosterone therapy in congestive heart failure
Weber, K. T., & Villarreal, D. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90238-8 · Cited by 108 · see citing works
Tsunoda, K., Abe, K., Hagino, T., Omata, K., Misawa, S., Imai, Y., & YOSHINAGA, K. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.1.28 · Cited by 106 · see citing works
Aldosterone-receptor antagonism in hypertension
Jansen, P. M., Danser, A. J., Imholz, B. P. M., & van den Meiracker, A. H. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832810ed · Cited by 91 · see citing works
Pitt, B., Ferreira, J. P., & Zannad, F. M. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw016 · Cited by 90 · see citing works
Epstein, M. (2001) · Journal of Hypertension · doi:10.1097/00004872-200105000-00001 · Cited by 87 · see citing works
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
Patel, B. M., & Mehta, A. A. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.034 · Cited by 86 · see citing works
Cohn, J. N., Anand, I. S., Latini, R., Masson, S., Chiang, Y., & Glazer, R. D. (2003) · Circulation · doi:10.1161/01.cir.0000091234.45664.62 · Cited by 86 · see citing works
Aldosterone: Cardiovascular assault
Struthers, A. D. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129969 · Cited by 85 · see citing works
Liu, L. C. Y., Schutte, E., Gansevoort, R. T., van der Meer, P., & Voors, A. A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1059819 · Cited by 84 · see citing works
Young, M. J., & Funder, J. W. (2002) · Journal of Hypertension · doi:10.1097/00004872-200208000-00002 · Cited by 84 · see citing works
Álvarez-Álvarez, B., Abad-Cardiel, M., Fernández‐Cruz, A., & Claros, N. M. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833d4c99 · Cited by 82 · see citing works
Young, M. J., & Funder, J. W. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00270-8 · Cited by 81 · see citing works
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Newman, J. D., O’Meara, E., Böhm, M., Savarese, G., Kelly, P. R., Vardeny, O., Allen, L. A., Lancellotti, P., Gottlieb, S. S., Samad, Z. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.033 · Cited by 84 · see citing works
Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys
Jaggi, J. S., Seshan, S. V., McDevitt, M. R., Sgouros, G., Hyjek, E. M., & Scheinberg, D. A. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.11.036 · Cited by 78 · see citing works
Queisser, N., & Schupp, N. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.011 · Cited by 77 · see citing works
Johnson, A. K., & Grippo, A. J. (2006) · PubMed · Cited by 75 · see citing works
Edelmann, F., Schmidt, A. G., Gelbrich, G., Binder, L., Herrmann‐Lingen, C., Halle, M., Hasenfuss, G. P., Wachter, R., & Pieske, B. M. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq087 · Cited by 75 · see citing works
Hostetter, T. H., Rosenberg, M. E., Ibrahim, H. N., & Juknevicius, I. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200101000-00016 · Cited by 72 · see citing works
Brown, J., de Boer, I. H., Robinson-Cohen, C., Siscovick, D. S., Kestenbaum, B., Allison, M., & Vaidya, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3949 · Cited by 71 · see citing works
Schäfer, A. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00333-x · Cited by 70 · see citing works
Multiple Endocrine Regulation by Bone Morphogenetic Protein System
Otsuka, F. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-310 · Cited by 69 · see citing works
The effect of low-dose spironolactone on resistant hypertension
Engbæk, M., Hjerrild, M., Hallas, J., & Jacobsen, I. A. (2010) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2010.10.001 · Cited by 68 · see citing works
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157 · see citing works
Sato, A., Hayashi, M., & Saruta, T. (2002) · Hypertension Research · doi:10.1291/hypres.25.837 · Cited by 65 · see citing works
Cook, C. S., Berry, L., Kim, D. H., Burton, E. G., Hribar, J. D., & Zhang, L. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1344 · Cited by 63 · see citing works
The role of the AT2 receptor in hypertension
Siragy, H. M. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)00274-0 · Cited by 61 · see citing works
Sato, A., Suzuki, Y., & Saruta, T. (1999) · Hypertension Research · doi:10.1291/hypres.22.17 · Cited by 61 · see citing works
Bauersachs, J. K., Fraccarollo, D., Ertl, G., Gretz, N., Wehling, M., & Christ, M. (2000) · Circulation · doi:10.1161/01.cir.102.19.2325 · Cited by 61 · see citing works
du Cailar, G., Fesler, P., Ribstein, J., & Mimran, A. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.159277 · Cited by 59 · see citing works
Ménard, J., Rigel, D. F., Watson, C. E., Jeng, A. Y., Fu, F., Beil, M. E., Liu, J., Chen, W., Hu, C.-W., Leung-Chu, J., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0340-9 · Cited by 59 · see citing works
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives
Epstein, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg339 · Cited by 59 · see citing works
Heart Failure: A Class Review of Pharmacotherapy.
Shah, A. A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. P. (2017) · PubMed Central · Cited by 55 · see citing works
Inhibition of the renin–angiotensin system and target organ protection
Iwanami, J., Mogi, M., Iwai, M., & Horiuchi, M. (2009) · Hypertension Research · doi:10.1038/hr.2009.5 · Cited by 56 · see citing works
Antihypertensive effect of the bovine casein-derived peptide Met-Lys-Pro
Yamada, A., Sakurai, T., Ochi, D., Mitsuyama, E., Yamauchi, K., & Abe, F. (2014) · Food Chemistry · doi:10.1016/j.foodchem.2014.09.098 · Cited by 55 · see citing works
Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure
Rocha, R., & Williams, G. H. (2002) · Drugs · doi:10.2165/00003495-200262050-00001 · Cited by 55 · see citing works
Crompton, M., Ferguson, J., Ramnath, R. D., Onions, K. L., Ogier, A. S., Gamez, M., Down, C. J., Skinner, L., Wong, K., Dixon, L. K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.154164 · Cited by 52 · see citing works
Kurrelmeyer, K. M., Ashton, Y. P., Xu, J., Nagueh, S. F., Torre‐Amione, G., & Deswal, A. M. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.05.010 · Cited by 52 · see citing works
Meredith, E. L., Ksander, G. M., Monovich, L. G., Papillon, J. P. N., Liu, Q., Miranda, K., Morris, P., Rao, C., Burgis, R., Capparelli, M. P., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400324c · Cited by 51 · see citing works
Hara, Y., Hamada, M., Shigematsu, Y., Suzuki, M., Kodama, K., Kuwahara, T., Hashida, H., Ikeda, S., Ohtsuka, T., Hiasa, G., et al. (2000) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.64.365 · Cited by 51 · see citing works
Potential Applications of Food Derived Bioactive Peptides in Management of Health
Dhaval, A., Yadav, N., & Purwar, S. (2016) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-016-9514-z · Cited by 51 · see citing works
Imagawa, K., Okayama, S., Takaoka, M., Kawata, H., Naya, N., Nakajima, T., Horii, M., Uemura, S., & Saito, Y. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000197539.12685.f5 · Cited by 50 · see citing works
Ravis, W. R., Reid, S. R., Sica, D. A., & Tolbert, D. S. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005275894 · Cited by 49 · see citing works
Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics
Costello‐Boerrigter, L. C., Boerrigter, G., & Burnett, J. C. J. (2003) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00181-5 · Cited by 47 · see citing works
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Lytvyn, Y., Godoy, L. C., Scholtes, R. A., van Raalte, D. H., & Cherney, D. Z. I. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1123-8 · Cited by 47 · see citing works
Kobayashi, M., Pitt, B., Ferreira, J. P., Rossignol, P., Girerd, N., & Zannad, F. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf225 · Cited by 50 · see citing works
Nagase, M. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0298-8 · Cited by 43 · see citing works
Suzuki, H., Kanno, Y., Kaneko, K., Kaneko, M., Kotaki, S., Mimura, T., & Takane, H. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2004.00142.x · Cited by 43 · see citing works
Angiotensin converting enzyme inhibitors. I. Pharmacology
Kostis, J. B. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90747-8 · Cited by 43 · see citing works
Dual inhibition of the renin system by aliskiren and valsartan
Birkenhäger, W. H., & Staessen, J. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61099-x · Cited by 41 · see citing works
Self-citationEplerenone: A Selective Aldosterone Blocker
Stier, C. T. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00114.x · Cited by 42 · see citing works
Importance of Neuroendocrine Activation in Chronic Heart Failure. Impact on Treatment Strategies
Swedberg, K. B. (2000) · European Journal of Heart Failure · doi:10.1016/s1388-9842(00)00102-1 · Cited by 42 · see citing works
Ruilope, L. M., Agarwal, R., Chan, J. C. N., Cooper, M. E., Gansevoort, R. T., Haller, H. G., Remuzzi, G., Rossing, P. R., Schmieder, R. E., Nowack, C., et al. (2014) · American Journal of Nephrology · doi:10.1159/000371497 · Cited by 41 · see citing works
The Forgotten Antiproteinuric Properties of Diuretics
Trujillo, H., Caravaca‐Fontán, F., Caro, J., Morales, E., & Praga, M. (2021) · American Journal of Nephrology · doi:10.1159/000517020 · Cited by 41 · see citing works
Iwashima, Y., Horio, T., Kuroda, S., Takishita, S., & Kawano, Y. (2002) · Hypertension Research · doi:10.1291/hypres.25.49 · Cited by 40 · see citing works
Aldosterone antagonists for people with chronic kidney disease requiring dialysis
Hasegawa, T., Nishiwaki, H., Ota, E., Levack, W., & Noma, H. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013109.pub2 · Cited by 38 · see citing works
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy
Zannad, F. M. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90243-6 · Cited by 39 · see citing works
Aldosterone as a target in congestive heart failure.
Rajagopalan, S., & Pitt, B. (2003) · The Medical clinics of North America · doi:10.1016/s0025-7125(02)00183-9 · Cited by 38 · see citing works
Aldosterone and Aldosterone Antagonism in Cardiovascular Disease
Stier, C. T., Koenig, S., Lee, D. Y., Chawla, M. K., & Frishman, W. H. (2003) · Heart Disease · doi:10.1097/01.hdx.0000061698.20666.aa · Cited by 38 · see citing works
- Authors
- STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A.
- ORCID
- STAESSEN, J.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 1981-12-01
- Volume
- 91
- Issue
- 3
- Pages
- 457-465
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W1971680322
- Cited by
- 339
- References
- 0
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 10 · 2014: 20 · 2013: 7 · 2012: 14
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- aldosterone, captopril, ACE inhibitors, hypertension, plasma renin activity, renin-angiotensin system, long-term drug therapy, hypotension
- MeSH terms
- Adult, Aldosterone, Angiotensin II, Captopril, Depression, Chemical, Female, Humans, Hypertension, Male, Middle Aged, Proline, Renin, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
